Vistagen Therapeutics announced on June 9, 2026, that its clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has reached the minimum patient exposures recommended under the ICH E1 international regulatory safety database standard. The company operates in the biotechnology industry and develops pharmaceutical products.
